01643nas a2200229   4500000000100000008004100001260001300042653001100055653002300066653001200089653002500101653002500126653002500151653003900176653000900215100001400224245006500238300001000303490000800313520107800321022001401399       2012                            d  c2012 Dec10aHumans10aLeprostatic Agents10aleprosy10aLeprosy, lepromatous10aLeprosy, Tuberculoid10aMycobacterium leprae10aPeripheral Nervous System Diseases10aSkin1 aFlageul B00a[Diagnosis and treatment of leprous neuropathy in practice].  a960-60 v1683 a<p>Leprosy still affects 240,000 persons every year in the world. It is a particularly common cause of neuropathy and severe disabilities in developing countries. With increasing migration, new cases of leprosy are regularly diagnosed in developed countries, where it still remains rare and so underestimated. Cutaneo-nevritic leprosy is the most frequent form of leprosy. It may be diagnosed by the clinical features and the cutaneous histology and bacteriology. Neuritic leprosy without obvious skin lesions is reported in 5 to 15% of leprosy patients. It must be suspected in persons from areas of endemic disease presenting with nerve thickening and associated nerve deficit. Nerve biopsy is essential for diagnosis. However search for bacilli in cutaneous samples may be of great help and avoid nerve biopsy. Acute and severe neuritis occurs during reactional states, reversal reaction (Type 1) and erythema nodosum leprosum (Type 2). Multidrug therapy is advocated. The treatment of acute neuropathy needs a supplementary medical and sometimes surgical treatment.</p>  a0035-3787